Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines

[Display omitted] N,N-Diallyltryptamine (DALT) and 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) are two tryptamines synthesized and tested by Alexander Shulgin. In self-experiments, 5-MeO-DALT was reported to be psychoactive in the 12–20mg range, while the unsubstituted compound DALT had few discern...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2016-02, Vol.26 (3), p.959-964
Hauptverfasser: Cozzi, Nicholas V., Daley, Paul F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 964
container_issue 3
container_start_page 959
container_title Bioorganic & medicinal chemistry letters
container_volume 26
creator Cozzi, Nicholas V.
Daley, Paul F.
description [Display omitted] N,N-Diallyltryptamine (DALT) and 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) are two tryptamines synthesized and tested by Alexander Shulgin. In self-experiments, 5-MeO-DALT was reported to be psychoactive in the 12–20mg range, while the unsubstituted compound DALT had few discernible effects in the 42–80mg range. Recently, 5-MeO-DALT has been used in nonmedical settings for its psychoactive effects, but these effects have been poorly characterized and little is known of its pharmacological properties. We extended the work of Shulgin by synthesizing additional 5-substituted-DALTs. We then compared them to DALT and 5-MeO-DALT for their binding affinities at 45 cloned receptors and transporter proteins. Based on in vitro binding affinity, we identified 27 potential receptor targets for the 5-substituted-DALT compounds. Five of the DALT compounds had affinity in the 10–80nM range for serotonin 5-HT1A and 5-HT2B receptors, while the affinity of DALT itself at 5-HT1A receptors was slightly lower at 100nM. Among the 5-HT2 subtypes, the weakest affinity was at 5-HT2A receptors, spanning 250–730nM. Five of the DALT compounds had affinity in the 50–400nM range for serotonin 5-HT1D, 5-HT6, and 5-HT7 receptors; again, it was the unsubstituted DALT that had the weakest affinity at all three subtypes. The test drugs had even weaker affinity for 5-HT1B, 5-HT1E, and 5-HT5A subtypes and little or no affinity for the 5-HT3 subtype. These compounds also had generally nanomolar affinities for adrenergic α2A, α2B, and α2C receptors, sigma receptors σ1 and σ2, histamine H1 receptors, and norepinephrine and serotonin uptake transporters. They also bound to other targets in the nanomolar-to-low micromolar range. Based on these binding results, it is likely that multiple serotonin receptors, as well as several nonserotonergic sites are important for the psychoactive effects of DALT drugs. To learn whether any quantitative structure–affinity relationships existed, we evaluated correlations among physicochemical properties of the congeneric 5-substituted-DALT compounds. The descriptors included electronic (σp), hydrophobic (π), and steric (CMR) parameters. The binding affinity at 5-HT1A, 5-HT1D, 5-HT7, and κ opioid receptors was positively correlated with the steric volume parameter CMR. At α2A, α2B, and α2C receptors, and at the histamine H1 receptor, binding affinity was correlated with the Hammett substituent parameter σp; higher affinity was associated with l
doi_str_mv 10.1016/j.bmcl.2015.12.053
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1768581989</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960894X1530367X</els_id><sourcerecordid>1768581989</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-78154efa0a67bfece180d1e613f9948283472bca45611c44915f299c95280e6b3</originalsourceid><addsrcrecordid>eNqNkc-K1TAUh4MoznX0BVxIly5sTdIkTcCNDOMfGEYQBXchTU80lzTtJOnAdeU7-IY-ibnc0aW4Oot8vx_n5EPoKcEdwUS83HfjbENHMeEdoR3m_T20I0ywtmeY30c7rARupWJfztCjnPcYE4YZe4jOqBh6NUiyQ98_goW1LKkZfZx8_NqsaXE-QG5MnJqbzcTiiyn-Fppc0mbLluDXj5_GOR99OTQJQn1dYv7m19wsrsnLDA1v8zbmmtwKTO31i-t28iaEQyjpsBYz-wj5MXrgTMjw5G6eo89vLj9dvGuvPrx9f_H6qrWcqtLWNTkDZ7ARw-jqtkTiiYAgvVOKSSp7NtDRGsYFIZYxRbijSlnFqcQgxv4cPT_11stuNshFzz5bCMFEWLasySAkl0RJ9T8oVpTxHleUnlCblpwTOL0mP5t00ATrox6910c9-qhHE6qrnhp6dte_jTNMfyN_fFTg1QmA-iG3HpLO1kO0MPkEtuhp8f_q_w17aaQ-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760924530</pqid></control><display><type>article</type><title>Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cozzi, Nicholas V. ; Daley, Paul F.</creator><creatorcontrib>Cozzi, Nicholas V. ; Daley, Paul F.</creatorcontrib><description>[Display omitted] N,N-Diallyltryptamine (DALT) and 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) are two tryptamines synthesized and tested by Alexander Shulgin. In self-experiments, 5-MeO-DALT was reported to be psychoactive in the 12–20mg range, while the unsubstituted compound DALT had few discernible effects in the 42–80mg range. Recently, 5-MeO-DALT has been used in nonmedical settings for its psychoactive effects, but these effects have been poorly characterized and little is known of its pharmacological properties. We extended the work of Shulgin by synthesizing additional 5-substituted-DALTs. We then compared them to DALT and 5-MeO-DALT for their binding affinities at 45 cloned receptors and transporter proteins. Based on in vitro binding affinity, we identified 27 potential receptor targets for the 5-substituted-DALT compounds. Five of the DALT compounds had affinity in the 10–80nM range for serotonin 5-HT1A and 5-HT2B receptors, while the affinity of DALT itself at 5-HT1A receptors was slightly lower at 100nM. Among the 5-HT2 subtypes, the weakest affinity was at 5-HT2A receptors, spanning 250–730nM. Five of the DALT compounds had affinity in the 50–400nM range for serotonin 5-HT1D, 5-HT6, and 5-HT7 receptors; again, it was the unsubstituted DALT that had the weakest affinity at all three subtypes. The test drugs had even weaker affinity for 5-HT1B, 5-HT1E, and 5-HT5A subtypes and little or no affinity for the 5-HT3 subtype. These compounds also had generally nanomolar affinities for adrenergic α2A, α2B, and α2C receptors, sigma receptors σ1 and σ2, histamine H1 receptors, and norepinephrine and serotonin uptake transporters. They also bound to other targets in the nanomolar-to-low micromolar range. Based on these binding results, it is likely that multiple serotonin receptors, as well as several nonserotonergic sites are important for the psychoactive effects of DALT drugs. To learn whether any quantitative structure–affinity relationships existed, we evaluated correlations among physicochemical properties of the congeneric 5-substituted-DALT compounds. The descriptors included electronic (σp), hydrophobic (π), and steric (CMR) parameters. The binding affinity at 5-HT1A, 5-HT1D, 5-HT7, and κ opioid receptors was positively correlated with the steric volume parameter CMR. At α2A, α2B, and α2C receptors, and at the histamine H1 receptor, binding affinity was correlated with the Hammett substituent parameter σp; higher affinity was associated with larger σp values. At the σ2 receptor, higher affinity was correlated with increasing π. These correlations should aid in the development of more potent and selective drugs within this family of compounds.</description><identifier>ISSN: 0960-894X</identifier><identifier>EISSN: 1464-3405</identifier><identifier>DOI: 10.1016/j.bmcl.2015.12.053</identifier><identifier>PMID: 26739781</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>5-Methoxy-N,N-diallyltryptamine ; Allyl Compounds - chemistry ; Allyl Compounds - metabolism ; Binding Sites ; DALT ; Hallucinogen ; Kinetics ; N,N-Diallyltryptamine ; Protein Binding ; Psychedelic ; Psychopharmacology ; QSAR ; Quantitative Structure-Activity Relationship ; Receptor binding ; Receptors, Opioid - chemistry ; Receptors, Opioid - metabolism ; Receptors, Serotonin - chemistry ; Receptors, Serotonin - metabolism ; Receptors, sigma - chemistry ; Receptors, sigma - metabolism ; Tryptamine ; Tryptamines - chemistry ; Tryptamines - metabolism</subject><ispartof>Bioorganic &amp; medicinal chemistry letters, 2016-02, Vol.26 (3), p.959-964</ispartof><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-78154efa0a67bfece180d1e613f9948283472bca45611c44915f299c95280e6b3</citedby><cites>FETCH-LOGICAL-c529t-78154efa0a67bfece180d1e613f9948283472bca45611c44915f299c95280e6b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bmcl.2015.12.053$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26739781$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cozzi, Nicholas V.</creatorcontrib><creatorcontrib>Daley, Paul F.</creatorcontrib><title>Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines</title><title>Bioorganic &amp; medicinal chemistry letters</title><addtitle>Bioorg Med Chem Lett</addtitle><description>[Display omitted] N,N-Diallyltryptamine (DALT) and 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) are two tryptamines synthesized and tested by Alexander Shulgin. In self-experiments, 5-MeO-DALT was reported to be psychoactive in the 12–20mg range, while the unsubstituted compound DALT had few discernible effects in the 42–80mg range. Recently, 5-MeO-DALT has been used in nonmedical settings for its psychoactive effects, but these effects have been poorly characterized and little is known of its pharmacological properties. We extended the work of Shulgin by synthesizing additional 5-substituted-DALTs. We then compared them to DALT and 5-MeO-DALT for their binding affinities at 45 cloned receptors and transporter proteins. Based on in vitro binding affinity, we identified 27 potential receptor targets for the 5-substituted-DALT compounds. Five of the DALT compounds had affinity in the 10–80nM range for serotonin 5-HT1A and 5-HT2B receptors, while the affinity of DALT itself at 5-HT1A receptors was slightly lower at 100nM. Among the 5-HT2 subtypes, the weakest affinity was at 5-HT2A receptors, spanning 250–730nM. Five of the DALT compounds had affinity in the 50–400nM range for serotonin 5-HT1D, 5-HT6, and 5-HT7 receptors; again, it was the unsubstituted DALT that had the weakest affinity at all three subtypes. The test drugs had even weaker affinity for 5-HT1B, 5-HT1E, and 5-HT5A subtypes and little or no affinity for the 5-HT3 subtype. These compounds also had generally nanomolar affinities for adrenergic α2A, α2B, and α2C receptors, sigma receptors σ1 and σ2, histamine H1 receptors, and norepinephrine and serotonin uptake transporters. They also bound to other targets in the nanomolar-to-low micromolar range. Based on these binding results, it is likely that multiple serotonin receptors, as well as several nonserotonergic sites are important for the psychoactive effects of DALT drugs. To learn whether any quantitative structure–affinity relationships existed, we evaluated correlations among physicochemical properties of the congeneric 5-substituted-DALT compounds. The descriptors included electronic (σp), hydrophobic (π), and steric (CMR) parameters. The binding affinity at 5-HT1A, 5-HT1D, 5-HT7, and κ opioid receptors was positively correlated with the steric volume parameter CMR. At α2A, α2B, and α2C receptors, and at the histamine H1 receptor, binding affinity was correlated with the Hammett substituent parameter σp; higher affinity was associated with larger σp values. At the σ2 receptor, higher affinity was correlated with increasing π. These correlations should aid in the development of more potent and selective drugs within this family of compounds.</description><subject>5-Methoxy-N,N-diallyltryptamine</subject><subject>Allyl Compounds - chemistry</subject><subject>Allyl Compounds - metabolism</subject><subject>Binding Sites</subject><subject>DALT</subject><subject>Hallucinogen</subject><subject>Kinetics</subject><subject>N,N-Diallyltryptamine</subject><subject>Protein Binding</subject><subject>Psychedelic</subject><subject>Psychopharmacology</subject><subject>QSAR</subject><subject>Quantitative Structure-Activity Relationship</subject><subject>Receptor binding</subject><subject>Receptors, Opioid - chemistry</subject><subject>Receptors, Opioid - metabolism</subject><subject>Receptors, Serotonin - chemistry</subject><subject>Receptors, Serotonin - metabolism</subject><subject>Receptors, sigma - chemistry</subject><subject>Receptors, sigma - metabolism</subject><subject>Tryptamine</subject><subject>Tryptamines - chemistry</subject><subject>Tryptamines - metabolism</subject><issn>0960-894X</issn><issn>1464-3405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc-K1TAUh4MoznX0BVxIly5sTdIkTcCNDOMfGEYQBXchTU80lzTtJOnAdeU7-IY-ibnc0aW4Oot8vx_n5EPoKcEdwUS83HfjbENHMeEdoR3m_T20I0ywtmeY30c7rARupWJfztCjnPcYE4YZe4jOqBh6NUiyQ98_goW1LKkZfZx8_NqsaXE-QG5MnJqbzcTiiyn-Fppc0mbLluDXj5_GOR99OTQJQn1dYv7m19wsrsnLDA1v8zbmmtwKTO31i-t28iaEQyjpsBYz-wj5MXrgTMjw5G6eo89vLj9dvGuvPrx9f_H6qrWcqtLWNTkDZ7ARw-jqtkTiiYAgvVOKSSp7NtDRGsYFIZYxRbijSlnFqcQgxv4cPT_11stuNshFzz5bCMFEWLasySAkl0RJ9T8oVpTxHleUnlCblpwTOL0mP5t00ATrox6910c9-qhHE6qrnhp6dte_jTNMfyN_fFTg1QmA-iG3HpLO1kO0MPkEtuhp8f_q_w17aaQ-</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Cozzi, Nicholas V.</creator><creator>Daley, Paul F.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20160201</creationdate><title>Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines</title><author>Cozzi, Nicholas V. ; Daley, Paul F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-78154efa0a67bfece180d1e613f9948283472bca45611c44915f299c95280e6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>5-Methoxy-N,N-diallyltryptamine</topic><topic>Allyl Compounds - chemistry</topic><topic>Allyl Compounds - metabolism</topic><topic>Binding Sites</topic><topic>DALT</topic><topic>Hallucinogen</topic><topic>Kinetics</topic><topic>N,N-Diallyltryptamine</topic><topic>Protein Binding</topic><topic>Psychedelic</topic><topic>Psychopharmacology</topic><topic>QSAR</topic><topic>Quantitative Structure-Activity Relationship</topic><topic>Receptor binding</topic><topic>Receptors, Opioid - chemistry</topic><topic>Receptors, Opioid - metabolism</topic><topic>Receptors, Serotonin - chemistry</topic><topic>Receptors, Serotonin - metabolism</topic><topic>Receptors, sigma - chemistry</topic><topic>Receptors, sigma - metabolism</topic><topic>Tryptamine</topic><topic>Tryptamines - chemistry</topic><topic>Tryptamines - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cozzi, Nicholas V.</creatorcontrib><creatorcontrib>Daley, Paul F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Bioorganic &amp; medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cozzi, Nicholas V.</au><au>Daley, Paul F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines</atitle><jtitle>Bioorganic &amp; medicinal chemistry letters</jtitle><addtitle>Bioorg Med Chem Lett</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>26</volume><issue>3</issue><spage>959</spage><epage>964</epage><pages>959-964</pages><issn>0960-894X</issn><eissn>1464-3405</eissn><abstract>[Display omitted] N,N-Diallyltryptamine (DALT) and 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) are two tryptamines synthesized and tested by Alexander Shulgin. In self-experiments, 5-MeO-DALT was reported to be psychoactive in the 12–20mg range, while the unsubstituted compound DALT had few discernible effects in the 42–80mg range. Recently, 5-MeO-DALT has been used in nonmedical settings for its psychoactive effects, but these effects have been poorly characterized and little is known of its pharmacological properties. We extended the work of Shulgin by synthesizing additional 5-substituted-DALTs. We then compared them to DALT and 5-MeO-DALT for their binding affinities at 45 cloned receptors and transporter proteins. Based on in vitro binding affinity, we identified 27 potential receptor targets for the 5-substituted-DALT compounds. Five of the DALT compounds had affinity in the 10–80nM range for serotonin 5-HT1A and 5-HT2B receptors, while the affinity of DALT itself at 5-HT1A receptors was slightly lower at 100nM. Among the 5-HT2 subtypes, the weakest affinity was at 5-HT2A receptors, spanning 250–730nM. Five of the DALT compounds had affinity in the 50–400nM range for serotonin 5-HT1D, 5-HT6, and 5-HT7 receptors; again, it was the unsubstituted DALT that had the weakest affinity at all three subtypes. The test drugs had even weaker affinity for 5-HT1B, 5-HT1E, and 5-HT5A subtypes and little or no affinity for the 5-HT3 subtype. These compounds also had generally nanomolar affinities for adrenergic α2A, α2B, and α2C receptors, sigma receptors σ1 and σ2, histamine H1 receptors, and norepinephrine and serotonin uptake transporters. They also bound to other targets in the nanomolar-to-low micromolar range. Based on these binding results, it is likely that multiple serotonin receptors, as well as several nonserotonergic sites are important for the psychoactive effects of DALT drugs. To learn whether any quantitative structure–affinity relationships existed, we evaluated correlations among physicochemical properties of the congeneric 5-substituted-DALT compounds. The descriptors included electronic (σp), hydrophobic (π), and steric (CMR) parameters. The binding affinity at 5-HT1A, 5-HT1D, 5-HT7, and κ opioid receptors was positively correlated with the steric volume parameter CMR. At α2A, α2B, and α2C receptors, and at the histamine H1 receptor, binding affinity was correlated with the Hammett substituent parameter σp; higher affinity was associated with larger σp values. At the σ2 receptor, higher affinity was correlated with increasing π. These correlations should aid in the development of more potent and selective drugs within this family of compounds.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26739781</pmid><doi>10.1016/j.bmcl.2015.12.053</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0960-894X
ispartof Bioorganic & medicinal chemistry letters, 2016-02, Vol.26 (3), p.959-964
issn 0960-894X
1464-3405
language eng
recordid cdi_proquest_miscellaneous_1768581989
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects 5-Methoxy-N,N-diallyltryptamine
Allyl Compounds - chemistry
Allyl Compounds - metabolism
Binding Sites
DALT
Hallucinogen
Kinetics
N,N-Diallyltryptamine
Protein Binding
Psychedelic
Psychopharmacology
QSAR
Quantitative Structure-Activity Relationship
Receptor binding
Receptors, Opioid - chemistry
Receptors, Opioid - metabolism
Receptors, Serotonin - chemistry
Receptors, Serotonin - metabolism
Receptors, sigma - chemistry
Receptors, sigma - metabolism
Tryptamine
Tryptamines - chemistry
Tryptamines - metabolism
title Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A14%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Receptor%20binding%20profiles%20and%20quantitative%20structure%E2%80%93affinity%20relationships%20of%20some%205-substituted-N,N-diallyltryptamines&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry%20letters&rft.au=Cozzi,%20Nicholas%20V.&rft.date=2016-02-01&rft.volume=26&rft.issue=3&rft.spage=959&rft.epage=964&rft.pages=959-964&rft.issn=0960-894X&rft.eissn=1464-3405&rft_id=info:doi/10.1016/j.bmcl.2015.12.053&rft_dat=%3Cproquest_cross%3E1768581989%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760924530&rft_id=info:pmid/26739781&rft_els_id=S0960894X1530367X&rfr_iscdi=true